From Semaglutide to Retatrutide: The GLP-1 Agonist Research Landscape in 2026

The Physiological Origin of GLP-1 and Early Pharmaceutical Engineering

Glucagon-like peptide-1 is an incretin hormone secreted primarily by L-cells in the distal small intestine and colon in response to nutrient ingestion. Its physiological role encompasses insulin secretion amplification in a glucose-dependent manner, glucagon suppression, gastric emptying deceleration, and satiety signalling through central nervous system pathways. The glucose-dependent nature of its insulinotropic effect (the fact that it only drives insulin release when blood glucose is already elevated) is what made it an attractive pharmacological target, because that property theoretically limits hypoglycaemia risk.

The first GLP-1-based pharmacological agent derived not from human GLP-1 itself but from exendin-4, a peptide found in the saliva of the Gila monster lizard. Exendin-4 shares about 53 percent sequence homology with human GLP-1 but is considerably more resistant to enzymatic degradation. This discovery in the early 1990s provided the template for the first generation of GLP-1 receptor agonists, culminating in exenatide. The pharmaceutical engineering challenge then became not finding the right receptor target, which was already established, but building molecules that could survive long enough in human circulation to be therapeutically useful.

The DPP-IV Stability Problem and How It Was Solved

Native human GLP-1 has a circulating half-life of approximately two minutes. The enzyme responsible for its rapid inactivation is dipeptidyl peptidase IV, or DPP-IV, which cleaves the alanine at position 2 from the N-terminus of GLP-1, rendering the peptide biologically inactive. This extreme brevity made native GLP-1 pharmacologically impractical for therapeutic use. An infusion could produce useful effects, but an injectable or oral formulation that lasted hours or days required a structurally modified molecule.

The pharmaceutical solutions to this problem followed two parallel tracks. The first was to engineer peptides with modified N-terminal residues that DPP-IV could not recognise: replacing the alanine at position 2 with amino-isobutyric acid, as in semaglutide, prevents cleavage. The second was fatty-acid conjugation: attaching a long-chain fatty acid moiety to the peptide backbone drives non-covalent binding to albumin in the circulation, creating a depot effect that dramatically extends half-life. Semaglutide's combination of both strategies (DPP-IV-resistant backbone plus C-18 fatty di-acid conjugate) produced a molecule with a half-life of approximately one week, enabling once-weekly subcutaneous injection or, in modified form, oral daily dosing.

GIP Receptor — Once Dismissed, Now Central

Glucose-dependent insulinotropic polypeptide, the other principal incretin hormone, was long regarded as a secondary player. Early research suggested that GIP receptor agonism alone produced modest glycaemic benefits and may even promote fat storage through adipocyte mechanisms, a profile that made it seem like an undesirable target to add to GLP-1 agonism. This view was substantially revised by the observation that combined GLP-1 and GIP receptor activation produced weight loss and metabolic improvements that exceeded what either target achieved alone, and that the two receptors appeared to interact at both central and peripheral levels in ways that amplified each compound's individual effects.

Tirzepatide, approved by the FDA in 2022 for type 2 diabetes and in 2023 for obesity management, was the first molecule to exploit dual GIP and GLP-1 receptor co-agonism at scale. The SURPASS-2 trial compared Tirzepatide directly with semaglutide 1 mg in type 2 diabetes patients and found Tirzepatide superior on both glycaemic control and body weight reduction at the highest dose tested. The rehabilitation of the GIP receptor from a problematic target to a beneficial co-agonist is one of the more significant mechanistic revisions in incretin pharmacology over the past decade.

Adding Glucagon Agonism: What Retatrutide's Phase II Data Showed

Retatrutide is a triple agonist at GLP-1, GIP, and glucagon receptors. Adding glucagon agonism to the dual-agonist framework was mechanistically controversial because glucagon is broadly viewed as a hyperglycaemic hormone: it drives hepatic glucose output, which seems counterproductive in a metabolic therapy. The rationale for its inclusion rested on glucagon's less-discussed effects on energy expenditure: glucagon activates brown adipose tissue thermogenesis and increases hepatic fat oxidation, producing an energy-expenditure signal that could complement the appetite suppression of GLP-1.

Retatrutide's Phase II trial, published in 2023, showed mean weight loss exceeding 17 percent at 48 weeks in the highest-dose group, a result that compared favourably with tirzepatide's SURMOUNT-1 data. The glycaemic signal remained appropriate despite the glucagon component, suggesting that the glucose-dependent insulinotropic effects of co-administered GLP-1 and GIP activation adequately counterbalanced glucagon's hyperglycaemic tendency. The tolerability profile showed dose-dependent gastrointestinal adverse effects consistent with the drug class.

The SURMOUNT-1 / STEP 1 / SURPASS-2 Triad — What Head-to-Head Data Tells Us

Three landmark trials define the current evidence base. STEP 1, published in 2021, established semaglutide 2.4 mg weekly as producing approximately 15 percent mean body weight reduction in adults with obesity. This result substantially exceeded anything previously seen with a GLP-1 monotherapy at approved doses. SURMOUNT-1, published in 2022, showed tirzepatide producing up to 22 percent mean weight reduction at the highest dose, with superiority over semaglutide established in the subsequent SURPASS-2 comparison.

These three trials collectively demonstrate a dose-response and mechanism-response relationship: adding the GIP receptor to the GLP-1 target improves outcomes, and the magnitude of the improvement in the Phase III data is consistent with the hypothesis that dual agonism produces effects beyond simple additivity. The deep-dive on GLP-1 receptor signalling from exendin to triple agonism provides the receptor pharmacology underpinning each of these clinical findings in more detail than trial summaries typically offer.

Open Questions for the Next Phase of Incretin Research

Several mechanistic and clinical questions remain unresolved as of 2026. The cardiovascular outcome trials for tirzepatide are ongoing: the SURPASS-CVOT data are expected to establish whether the improved metabolic profile translates into reduced cardiovascular events at a similar magnitude to the LEADER and SELECT trials for GLP-1 monotherapies. Retatrutide remains in Phase III trials, and the completeness of its cardiovascular programme will determine its eventual regulatory position relative to tirzepatide.

Oral formulations of GLP-1-based therapies are a significant frontier: the absorption challenges are substantial for peptide molecules in the gastrointestinal tract, but semaglutide has demonstrated that the problem is solvable. Extending oral bioavailability to larger or more structurally complex triple agonists remains an active area.

From a research-protocol perspective, the practical question for 2026 is what the divergent regulatory statuses of these compounds mean for UK researchers: tirzepatide holds a licensed-drug status that retatrutide does not, and that distinction carries significant implications for how protocols involving each compound can be designed and reported.